Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians
Figure 3
(a–d) Gadoxetate acid-enhanced MRI in the precontrast, arterial, venous, and equilibrium phases of Hepatitis B virus carrier showing a nodule in segment 6 of the liver with early arterial enhancement and late-phase washout compatible with HCC. (e), (f) Gadoxetate acid-enhanced MRI in the hepatobiliary phase 10–20 minutes after injection, showing progressively hyperintense portions of the nodule, implying lesional uptake, in a heterogeneous pattern. Note the hypointense pseudocapsule. Final surgical histopathology showed moderately differentiated Edmondson-Steiner grade II HCC. (g) Coronal view.
